A study led by researchers at the Boston University School of Public Health has found that expanding legal access to marijuana may be linked to reduced daily opioid use among people who inject drugs. The findings, which come amid the ongoing opioid crisis, suggest that cannabis legalization could serve as a harm reduction tool.
The research examined data on individuals who inject opioids and other substances, comparing rates of daily opioid use in states with legal marijuana versus those without. Results indicated that states with legal recreational or medical marijuana had lower rates of daily opioid consumption among this population. While the study does not establish causation, it adds to a growing body of evidence that cannabis access may help curb opioid misuse.
Companies like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) are among those monitoring such research, as it could influence public policy and market demand. The cannabis industry has long argued that marijuana can serve as a safer alternative to opioids for pain management.
According to the Centers for Disease Control and Prevention, over 100,000 people died from drug overdoses in the United States in the 12-month period ending April 2021, with opioids involved in the majority of cases. Policy makers are increasingly exploring innovative approaches to address the crisis, including expanding access to cannabis.
The study's authors caution that more research is needed to understand the mechanisms behind the association. Potential explanations include individuals substituting marijuana for opioids to manage withdrawal symptoms or chronic pain, or reduced availability of illicit opioids in legal cannabis markets.
For more information on cannabis industry developments and research, visit CannabisNewsWire.com. The site provides daily updates on regulatory changes and market trends affecting the legalized cannabis sector.
